Cargando…
Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan
The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we descri...
Autores principales: | Gorman, Declan M., Lee, John, Payne, Colton D., Woodruff, Trent M., Clark, Richard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781173/ https://www.ncbi.nlm.nih.gov/pubmed/33398524 http://dx.doi.org/10.1007/s00726-020-02921-5 |
Ejemplares similares
-
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023) -
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023) -
SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate
por: Lo, Martin W, et al.
Publicado: (2022) -
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
por: De Leeuw, Elisabeth, et al.
Publicado: (2022) -
Synthesis, Characterisation and Antitumour Activity of Some Quercetin Analogues
por: Gadhwal, M. K., et al.
Publicado: (2013)